Chemistry:Mizacorat
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | AZD9567 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H28F2N4O3 |
| Molar mass | 494.543 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mizacorat (AZD9567) is an investigational selective glucocorticoid receptor modulator that has a better ratio of therapeutic effect to adverse effects compared to prednisolone according to preliminary studies. It is developed by AstraZeneca for rheumatoid arthritis.[1][2][3][4][5][6]
References
- ↑ van Laar, Jacob M.; Lei, Alejhandra; Safy‐Khan, Mary; Almquist, Joachim; Belfield, Graham; Edman, Karl; Öberg, Lisa; Angermann, Bastian R. et al. (23 October 2023). "AZD9567 versus prednisolone in patients with active rheumatoid arthritis: A phase IIa , randomized, double‐blind, efficacy, and safety study" (in en). Clinical and Translational Science 16 (12): 2494–2506. doi:10.1111/cts.13624. ISSN 1752-8054. PMID 37873558.
- ↑ Putra, Okky Dwichandra; Ottosson, Jenny; Nilsson Lill, Sten O.; Pettersen, Anna (5 January 2022). "Understanding Crystal Structures to Guide Form Selection of Active Pharmaceutical Ingredients: A Case Study of AZD9567". Crystal Growth & Design 22 (1): 535–546. doi:10.1021/acs.cgd.1c01124.
- ↑ Ripa, Lena; Edman, Karl; Dearman, Matthew; Edenro, Goran; Hendrickx, Ramon; Ullah, Victoria; Chang, Hui-Fang; Lepistö, Matti et al. (8 March 2018). "Discovery of a Novel Oral Glucocorticoid Receptor Modulator (AZD9567) with Improved Side Effect Profile". Journal of Medicinal Chemistry 61 (5): 1785–1799. doi:10.1021/acs.jmedchem.7b01690. PMID 29424542.
- ↑ Hegelund Myrbäck, Tove; Prothon, Susanne; Edman, Karl; Leander, Jacob; Hashemi, Mahdi; Dearman, Matthew; Edenro, Goran; Svanberg, Petter et al. (January 2020). "Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials" (in en). The Lancet Rheumatology 2 (1): e31–e41. doi:10.1016/S2665-9913(19)30103-1. https://doi.org/10.1016/S2665-9913(19)30103-1.
- ↑ Hendrickx, R.; Hegelund-Myrbäck, T.; Dearman, M.; Prothon, S.; Edenro, G.; Leander, J.; Fuhr, R.; Körnicke, T. et al. (1 June 2018). "SAT0245 Azd9567: a novel oral selective glucocorticoid receptor modulator, demonstrated to have an improved therapeutic ratio compared to prednisolone in pre-clinical studies, is safe and well tolerated in first clinical study." (in en). Annals of the Rheumatic Diseases 77 (Suppl 2): 984–985. doi:10.1136/annrheumdis-2018-eular.6360. ISSN 0003-4967. https://ard.bmj.com/content/77/Suppl_2/984.2.abstract.
- ↑ Almquist, Joachim; Sadiq, Muhammad Waqas; Eriksson, Ulf G.; Hegelund Myrbäck, Tove; Prothon, Susanne; Leander, Jacob (August 2020). "Estimation of Equipotent Doses for Anti‐Inflammatory Effects of Prednisolone and AZD9567, an Oral Selective Nonsteroidal Glucocorticoid Receptor Modulator" (in en). CPT: Pharmacometrics & Systems Pharmacology 9 (8): 444–455. doi:10.1002/psp4.12536. ISSN 2163-8306. PMID 32501650. PMC 7438818. https://doi.org/10.1002/psp4.12536.
 |  |
